14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.58 $20.11 Thursday, 2nd May 2024 DNLI stock ended at $16.81. This is 4.02% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 6.41% from a day low at $15.92 to a day high of $16.94.
90 days $14.58 $23.52
52 weeks $14.58 $33.31

Historical Denali Therapeutics Inc. prices

Date Open High Low Close Volume
Mar 06, 2018 $22.63 $22.99 $21.63 $21.96 259 397
Mar 05, 2018 $22.59 $22.99 $21.10 $22.55 319 618
Mar 02, 2018 $21.55 $22.99 $21.00 $22.59 233 908
Mar 01, 2018 $22.98 $23.00 $21.55 $21.57 331 671
Feb 28, 2018 $21.54 $23.44 $21.00 $22.89 288 978
Feb 27, 2018 $22.05 $22.11 $21.48 $21.51 269 842
Feb 26, 2018 $22.37 $23.20 $21.40 $22.16 243 505
Feb 23, 2018 $22.73 $23.30 $21.94 $22.40 309 736
Feb 22, 2018 $22.90 $23.39 $22.12 $22.42 176 063
Feb 21, 2018 $23.90 $24.78 $22.72 $23.02 176 724
Feb 20, 2018 $24.86 $25.79 $23.40 $23.68 247 238
Feb 16, 2018 $23.42 $25.02 $23.30 $24.80 381 343
Feb 15, 2018 $21.09 $23.55 $21.00 $23.34 207 421
Feb 14, 2018 $20.56 $21.18 $20.54 $20.93 51 295
Feb 13, 2018 $21.26 $21.29 $20.47 $20.59 76 732
Feb 12, 2018 $21.61 $21.78 $20.70 $21.22 100 358
Feb 09, 2018 $21.12 $21.62 $20.37 $21.49 176 139
Feb 08, 2018 $20.30 $21.00 $20.30 $20.89 173 264
Feb 07, 2018 $19.40 $20.48 $19.27 $20.27 237 819
Feb 06, 2018 $18.76 $19.93 $18.49 $19.38 236 764
Feb 05, 2018 $20.12 $20.85 $19.20 $19.26 168 024
Feb 02, 2018 $20.87 $20.87 $19.58 $20.39 145 891
Feb 01, 2018 $23.32 $23.66 $21.06 $21.18 136 911
Jan 31, 2018 $23.82 $24.00 $23.11 $23.26 383 208
Jan 30, 2018 $23.75 $23.93 $22.89 $23.67 372 951
Click to get the best stock tips daily for free!

About Denali Therapeutics Inc.

Denali Therapeutics. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ... DNLI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT